Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,585 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo:0.9% sodium chloride Clear all
Terminated Phase 4 Interventional Results available

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

NCT04738318
View directory record Official record
Conditions
Elbow Fracture
Interventions
Glucocorticoids, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 15, 2026, 10:35 PM EDT
Recruiting Phase 3 Interventional

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213
View directory record Official record
Conditions
Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Interventions
ADX-324, Placebo
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

NCT00317642
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
clofarabine (IV formulation), placebo, cytarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
55 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 15, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Results available

Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery

NCT00966654
View directory record Official record
Conditions
CABG
Interventions
Placebo, GLP-1 (7-36) amide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 3 Interventional

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

NCT06347016
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Infections
Interventions
Rhu-pGSN, normal saline
Drug
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 10:35 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

NCT03150420
View directory record Official record
Conditions
Calciphylaxis
Interventions
Sodium Thiosulfate, Placebo-Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Jacksonville, Florida • Chicago, Illinois • Maywood, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

NCT04767373
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Clesrovimab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 1 Year
Enrollment
3,632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
51
States / cities
Dothan, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 15, 2026, 10:35 PM EDT
Not listed Phase 2 Interventional

Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores

NCT03149783
View directory record Official record
Conditions
Pain, Postoperative, Delirium, Anesthesia, Local
Interventions
Ropivacaine HCL, sodium chloride
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

IVIG-eye Drops Treatment for Dry Eye Disease

NCT03992482
View directory record Official record
Conditions
Dry Eye
Interventions
Intravenous Immune Globulin (IVIG), Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 15, 2026, 10:35 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Early BOTOX After Spinal Cord Injury

NCT06793683
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Bladder chemodenervation (Botox), Bladder Sham (Saline) Injection Procedure
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

NCT02856854
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
EMB-001, Placebo, Cocaine IV, Saline IV
Drug
Lead sponsor
Embera NeuroTherapeutics, Inc.
Industry
Eligibility
21 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 15, 2026, 10:35 PM EDT
Not listed Not applicable Interventional

Efficacy of a Single Injection of CTM for Post-Operative CMC Arthritis

NCT06171529
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis Thumb Base Joint, Carpometacarpal Osteoarthritis, Thumb
Interventions
CTM, Placebo
Device · Other
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 15, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects

NCT01244880
View directory record Official record
Conditions
Healthy
Interventions
Saline, PF-02545920, Ketamine, Placebo
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

NCT02641561
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 15, 2026, 10:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

NCT05560477
View directory record Official record
Conditions
Meniscus Tear
Interventions
AM3101, Saline Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Stannsoporfin With Light Therapy for Newborn Babies With Jaundice

NCT01887327
View directory record Official record
Conditions
Jaundice, Neonatal, Hyperbilirubinemia, Neonatal
Interventions
Phototherapy, Stannsoporfin, Placebo
Procedure · Drug
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Hour to 72 Hours
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Colton, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BARDA Securing Anthrax Immunity For the Elderly

NCT03518125
View directory record Official record
Conditions
Anthrax
Interventions
BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo)
Biological · Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

NCT03014089
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1325, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380
View directory record Official record
Conditions
EoE, Eosinophilic Esophagitis
Interventions
Mepolizumab 300 mg, Mepolizumab 100 mg, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

NCT01095276
View directory record Official record
Conditions
Atelectasis, Ventilation, Mechanical
Interventions
Pulmozyme (nebulized dornase alpha), Saline
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Oct 15, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy

NCT02253810
View directory record Official record
Conditions
Dysplasia, Congenital Hip
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 15, 2026, 10:35 PM EDT